AEON Biopharma Advances BOTOX Biosimilar Development, Secures FDA Meeting Milestone

Retrieved on: 2024-11-13 21:11:58

Tags for this article:

Click the tags to see associated articles and topics

AEON Biopharma Advances BOTOX Biosimilar Development, Secures FDA Meeting Milestone. View article details on hiswai:

Excerpt

AEON Biopharma progresses with ABP-450 BOTOX biosimilar development, receiving FDA guidance on 351(k) pathway. Company plans Q4 2024 analytical ...

Article found on: www.stocktitan.net